• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向白细胞介素-17/白细胞介素-6轴可在体内/体外改变慢性淋巴细胞白血病的生长。

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.

作者信息

Zhu Fang, McCaw Lindsay, Spaner David E, Gorczynski Reginald M

机构信息

Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Transplant Research Division, Toronto General Hospital, Toronto, Canada.

Biology Platform, Sunnybrook Research Institute, Toronto, Canada.

出版信息

Leuk Res. 2018 Mar;66:28-38. doi: 10.1016/j.leukres.2018.01.006. Epub 2018 Jan 17.

DOI:10.1016/j.leukres.2018.01.006
PMID:29353760
Abstract

The tumor microenvironment (TME) is critical to the longevity of tumor B cells in chronic lymphocytic leukemia (CLL). Bone marrow mesenchymal stem cells (BMMSCs) and the cytokines they produce including IL-6 are important components of the TME in CLL. We found BMMSCs supported the survival of CLL cells in vitro through an IL-6 dependent mechanism. IL-17 which induces IL-6 generation in a variety of cells increased production of IL-6 both in CLL cells and BMMSCs in vitro. In a xenograft CLL mouse model, BMMSCs and the culture supernatant of BMMSCs increased engraftment of CLL cells through an IL-6 mediated mechanism with human recombinant IL-6 showing similar effects in vivo. Human recombinant IL-17 treatment also increased CLL engraftment in mice through an IL-6 mediated mechanism. Plasma of CLL patients showed elevated levels of both IL-6 and IL-17 by ELISA compared with healthy controls, with levels of IL-6 linearly correlated with IL-17 levels. CLL patients requiring fludarabine based chemotherapy expressed higher levels of IL-6 and IL-17, while CLL patients with the lowest levels of IgA/IgM had higher levels of IL-6, but not IL-17. These data imply an important role for the IL-17/IL-6 axis in CLL which could be therapeutic targets.

摘要

肿瘤微环境(TME)对于慢性淋巴细胞白血病(CLL)中肿瘤B细胞的存活至关重要。骨髓间充质干细胞(BMMSCs)及其产生的细胞因子(包括IL-6)是CLL中TME的重要组成部分。我们发现BMMSCs在体外通过依赖IL-6的机制支持CLL细胞的存活。IL-17可在多种细胞中诱导IL-6生成,在体外可增加CLL细胞和BMMSCs中IL-6的产生。在异种移植CLL小鼠模型中,BMMSCs和BMMSCs的培养上清液通过IL-6介导的机制增加CLL细胞的植入,人重组IL-6在体内显示出类似的作用。人重组IL-17治疗也通过IL-6介导的机制增加小鼠中CLL的植入。通过ELISA检测,CLL患者血浆中IL-6和IL-17水平均高于健康对照,IL-6水平与IL-17水平呈线性相关。需要基于氟达拉滨化疗的CLL患者表达较高水平的IL-6和IL-17,而IgA/IgM水平最低的CLL患者IL-6水平较高,但IL-17水平不高。这些数据表明IL-17/IL-6轴在CLL中起重要作用,可能成为治疗靶点。

相似文献

1
Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.靶向白细胞介素-17/白细胞介素-6轴可在体内/体外改变慢性淋巴细胞白血病的生长。
Leuk Res. 2018 Mar;66:28-38. doi: 10.1016/j.leukres.2018.01.006. Epub 2018 Jan 17.
2
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.利用新型抗 CXCR4 IgG1 抗体(PF-06747143)靶向慢性淋巴细胞白血病的 CXCR4 途径。
J Hematol Oncol. 2017 May 19;10(1):112. doi: 10.1186/s13045-017-0435-x.
3
Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice.可溶性 CD200 对在免疫功能低下的小鼠中植入慢性淋巴细胞白血病细胞至关重要。
Cancer Res. 2012 Oct 1;72(19):4931-43. doi: 10.1158/0008-5472.CAN-12-1390. Epub 2012 Aug 8.
4
Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.前明胶酶B/前基质金属蛋白酶-9的过表达影响迁移调节通路,并损害慢性淋巴细胞白血病细胞归巢至骨髓和脾脏。
J Leukoc Biol. 2014 Aug;96(2):185-99. doi: 10.1189/jlb.3HI0913-521R.
5
Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies.人慢性淋巴细胞白血病细胞在严重联合免疫缺陷小鼠中的植入:体内和体外研究
Leukemia. 1996 Aug;10(8):1370-6.
6
Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.先用苔藓抑素1后用2-氯脱氧腺苷序贯治疗人类慢性淋巴细胞白血病:临床前研究
Clin Cancer Res. 1998 Feb;4(2):445-53.
7
CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.CD126 与托珠单抗在慢性淋巴细胞白血病中的靶向治疗。
Clin Cancer Res. 2016 May 15;22(10):2462-9. doi: 10.1158/1078-0432.CCR-15-1139. Epub 2015 Dec 28.
8
Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia.白细胞介素-6抑制B慢性淋巴细胞白血病的细胞凋亡以及肿瘤坏死因子诱导的增殖。
Leuk Lymphoma. 1996 Jun;22(1-2):83-90, follow. 186, color plate VI. doi: 10.3109/10428199609051732.
9
Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.慢性淋巴细胞白血病细胞通过T-bet依赖机制对Th1细胞衍生的IFN-γ作出反应,从而表达CD38。
J Immunol. 2015 Jan 15;194(2):827-35. doi: 10.4049/jimmunol.1401350. Epub 2014 Dec 10.
10
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.TLR9 在慢性淋巴细胞白血病中的表达鉴定出一个促迁移亚群和新的治疗靶点。
Blood. 2021 Jun 3;137(22):3064-3078. doi: 10.1182/blood.2020005964.

引用本文的文献

1
Polyfunctional CD8CD226RUNX2 effector T cells are diminished in advanced stages of chronic lymphocytic leukemia.多功能CD8CD226RUNX2效应T细胞在慢性淋巴细胞白血病晚期减少。
Mol Oncol. 2025 May;19(5):1347-1370. doi: 10.1002/1878-0261.13793. Epub 2025 Jan 7.
2
Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.重塑肿瘤微环境中T细胞抑制性细胞因子格局:精准抗癌治疗的新前沿
Front Immunol. 2024 Aug 30;15:1418527. doi: 10.3389/fimmu.2024.1418527. eCollection 2024.
3
Inflammation mediated angiogenesis in chronic lymphocytic leukemia.
慢性淋巴细胞白血病中的炎症介导的血管生成。
Ann Hematol. 2024 Aug;103(8):2865-2875. doi: 10.1007/s00277-024-05781-1. Epub 2024 May 7.
4
Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia.从癌症动物模型到乳腺癌和慢性淋巴细胞白血病免疫治疗的数据转化。
Genes (Basel). 2024 Feb 25;15(3):292. doi: 10.3390/genes15030292.
5
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.白血病细胞分泌的白细胞介素-9 抑制慢性淋巴细胞白血病中细胞毒性 T 细胞介导的杀伤。
Cell Death Dis. 2024 Feb 15;15(2):144. doi: 10.1038/s41419-024-06528-6.
6
Mesenchymal stromal cell senescence in haematological malignancies.血液系统恶性肿瘤中的间充质基质细胞衰老
Cancer Metastasis Rev. 2023 Mar;42(1):277-296. doi: 10.1007/s10555-022-10069-9. Epub 2023 Jan 9.
7
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?Th17 细胞在慢性淋巴细胞白血病中的作用:是敌是友?
Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985.
8
Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia.评估细胞因子水平作为慢性淋巴细胞白血病患者的可能预测因素。
Rev Assoc Med Bras (1992). 2022 Nov 21;68(10):1364-1368. doi: 10.1590/1806-9282.20220260. eCollection 2022.
9
Identifying a novel ferroptosis-related prognostic score for predicting prognosis in chronic lymphocytic leukemia.鉴定新型铁死亡相关预后评分,用于预测慢性淋巴细胞白血病的预后。
Front Immunol. 2022 Oct 6;13:962000. doi: 10.3389/fimmu.2022.962000. eCollection 2022.
10
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.慢性淋巴细胞白血病(CLL)-T细胞相互作用的体外和体内模型:对药物测试的意义。
Cancers (Basel). 2022 Jun 23;14(13):3087. doi: 10.3390/cancers14133087.